钠-葡萄糖协同转运蛋白2介导的正常血糖性糖尿病酮症酸中毒揭示了一名被误诊为2型糖尿病患者的潜在自身免疫性糖尿病：一例病例报告
Sodium-glucose cotransporter-2-induced euglycemic diabetic ketoacidosis unmasks latent autoimmune diabetes in a patient misdiagnosed with type 2 diabetes mellitus: a case report.
作者信息
Vadasz Brian, Arazi Mattan, Shukha Yousef, Koren Ofir, Taher Riad
机构信息
The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Internal Medicine Department E, Rambam HealthCare Campus, Ein IbrahimUmm alfahm, POD 4147, 300100, Haifa, Israel.
出版信息
J Med Case Rep. 2021 Feb 14;15(1):62. doi: 10.1186/s13256-020-02607-2.
Abstract
BACKGROUND
Euglycemic diabetic ketoacidosis is an uncommon but life-threatening complication associated with the use of sodium-glucose cotransporter 2 inhibitors that causes lower than expected blood glucose levels typically seen in diabetic ketoacidosis.
CASE PRESENTATION
We present a case of 64-year-old Caucasian male patient previously diagnosed with type 2 diabetes treated with a sodium-glucose cotransporter 2 inhibitor who developed severe ketoacidosis. Serum glucose levels on initial presentation were slightly above normal baseline level. The patient was revealed to have latent autoimmune diabetes in adults.
CONCLUSION
This case highlights the importance of prescribing sodium-glucose cotransporter 2 inhibitors to the correct patient population and the significance of accurately differentiating between various types of diabetes.
摘要
背景
正常血糖性糖尿病酮症酸中毒是一种与使用钠-葡萄糖协同转运蛋白2抑制剂相关的罕见但危及生命的并发症，它会导致糖尿病酮症酸中毒中通常所见的血糖水平低于预期。
病例报告
我们报告一例64岁的白种男性患者，此前被诊断为2型糖尿病，接受钠-葡萄糖协同转运蛋白2抑制剂治疗，该患者发生了严重酮症酸中毒。初次就诊时的血清葡萄糖水平略高于正常基线水平。该患者被发现患有成人隐匿性自身免疫性糖尿病。
结论
本病例强调了为正确的患者群体开具钠-葡萄糖协同转运蛋白2抑制剂的重要性，以及准确区分各种类型糖尿病的意义。
相似文献
1
Sodium-glucose cotransporter-2-induced euglycemic diabetic ketoacidosis unmasks latent autoimmune diabetes in a patient misdiagnosed with type 2 diabetes mellitus: a case report.钠-葡萄糖协同转运蛋白2介导的正常血糖性糖尿病酮症酸中毒揭示了一名被误诊为2型糖尿病患者的潜在自身免疫性糖尿病：一例病例报告
J Med Case Rep. 2021 Feb 14;15(1):62. doi: 10.1186/s13256-020-02607-2.
2
Prevalence and Clinical Characteristics of Adults Presenting With Sodium-Glucose Cotransporter-2 Inhibitor-Associated Diabetic Ketoacidosis at a Canadian Academic Tertiary Care Hospital.在加拿大一家学术型三级保健医院中，钠-葡萄糖共转运蛋白 2 抑制剂相关糖尿病酮症酸中毒患者的患病率和临床特征。
Can J Diabetes. 2021 Apr;45(3):214-219. doi: 10.1016/j.jcjd.2020.08.100. Epub 2020 Aug 21.
3
Sodium-glucose cotransporter 2 inhibitor-induced euglycemic diabetic ketoacidosis in a patient with coronavirus disease 2019: a case report.钠-葡萄糖共转运蛋白 2 抑制剂致 2019 冠状病毒病患者血糖正常性糖尿病酮症酸中毒：1 例报告。
J Med Case Rep. 2022 Jan 4;16(1):17. doi: 10.1186/s13256-021-03232-3.
4
Euglycemic Diabetic Ketoacidosis Associated With SGLT2 Inhibitor Therapy: A Case Report.与 SGLT2 抑制剂治疗相关的血糖正常的糖尿病酮症酸中毒：病例报告。
AACN Adv Crit Care. 2023 Mar 15;34(1):27-32. doi: 10.4037/aacnacc2023830.
5
[Diabetic euglycemic ketosis or ketoacidosis in individuals with type 2 diabetes treated by SGLT2 inhibitors: A series of Belgian clinical cases].[2型糖尿病患者使用SGLT2抑制剂治疗后出现的糖尿病正常血糖性酮症或酮症酸中毒：比利时系列临床病例]
Rev Med Interne. 2020 Apr;41(4):226-231. doi: 10.1016/j.revmed.2019.12.006. Epub 2019 Dec 19.
6
Euglycemic Diabetic Ketoacidosis Associated With Sodium-Glucose Cotransporter Type 2 Inhibitors in Patients With Type 2 Diabetes Mellitus Receiving Oral Therapy.2型糖尿病口服治疗患者中与钠-葡萄糖协同转运蛋白2抑制剂相关的正常血糖性糖尿病酮症酸中毒
J Pharm Pract. 2019 Apr;32(2):240-243. doi: 10.1177/0897190017748049. Epub 2017 Dec 14.
7
Intraoperative Diagnosis of Sodium-Glucose Cotransporter 2 Inhibitor-Associated Euglycemic Diabetic Ketoacidosis: A Case Report.钠-葡萄糖共转运蛋白 2 抑制剂相关的血糖正常糖尿病酮症酸中毒的术中诊断：一例报告。
A A Pract. 2021 Jan 14;15(1):e01380. doi: 10.1213/XAA.0000000000001380.
8
SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：对原发性文献中糖尿病酮症酸中毒及相关危险因素的系统评价
Pharmacotherapy. 2017 Feb;37(2):187-194. doi: 10.1002/phar.1881. Epub 2017 Jan 16.
9
Euglycemic Ketoacidosis With Sodium-Glucose Cotransporter-2 Inhibitor.钠-葡萄糖协同转运蛋白2抑制剂所致正常血糖性酮症酸中毒
Am J Ther. 2018 Sep/Oct;25(5):e590-e591. doi: 10.1097/MJT.0000000000000602.
10
Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis.1 型糖尿病中钠-葡萄糖共转运蛋白 2 抑制作用的真实世界评估及糖尿病酮症酸中毒风险。
Diab Vasc Dis Res. 2022 Sep-Oct;19(5):14791641221130043. doi: 10.1177/14791641221130043.
引用本文的文献
1
Various classification methods for diabetes mellitus in the management of blood glucose control.血糖控制管理中糖尿病的各种分类方法。
World J Diabetes. 2025 May 15;16(5):103316. doi: 10.4239/wjd.v16.i5.103316.
本文引用的文献
1
SGLT2 inhibitor-induced euglycaemic diabetic ketoacidosis may be due to abrupt, severe and transient impaired glucose sensing in susceptible individuals with a hitherto unrecognised beta cell SGLT variant.SGLT2 抑制剂引起的血糖正常型糖尿病酮症酸中毒可能是由于易感个体中葡萄糖敏感性的突然、严重和短暂受损所致，这些个体存在尚未被认识到的β细胞 SGLT 变异。
Med Hypotheses. 2018 May;114:11-12. doi: 10.1016/j.mehy.2018.02.025. Epub 2018 Feb 24.
2
A Rose by Any Other Name: Ketoacidosis Due to SGLT2 Inhibitors Reveals Latent Autoimmune Diabetes.
Am J Med. 2018 Jan;131(1):e1-e3. doi: 10.1016/j.amjmed.2017.09.014. Epub 2017 Oct 2.
3
Ketoacidosis associated with SGLT2 inhibitor treatment: Analysis of FAERS data.与 SGLT2 抑制剂治疗相关的酮症酸中毒：FAERS 数据分析。
Diabetes Metab Res Rev. 2017 Nov;33(8). doi: 10.1002/dmrr.2924. Epub 2017 Sep 29.
4
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与 2 型糖尿病的心血管和肾脏事件。
N Engl J Med. 2017 Aug 17;377(7):644-657. doi: 10.1056/NEJMoa1611925. Epub 2017 Jun 12.
5
SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System.钠-葡萄糖协同转运蛋白2抑制剂与糖尿病酮症酸中毒：来自美国食品药品监督管理局不良事件报告系统的数据
Diabetologia. 2017 Aug;60(8):1385-1389. doi: 10.1007/s00125-017-4301-8. Epub 2017 May 12.
6
Euglycemic ketosis in patients with type 2 diabetes on SGLT2-inhibitor therapy-an emerging problem and solutions offered by diabetes technology.接受SGLT2抑制剂治疗的2型糖尿病患者的正常血糖性酮症——一个新出现的问题及糖尿病技术提供的解决方案
Endocrine. 2017 Apr;56(1):212-216. doi: 10.1007/s12020-017-1264-y. Epub 2017 Mar 17.
7
Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives.SGLT2抑制剂相关的酮症及糖尿病酮症酸中毒：基本机制与治疗前景
Diabetes Metab Res Rev. 2017 Jul;33(5). doi: 10.1002/dmrr.2886. Epub 2017 Feb 23.
8
SGLT2 Inhibitor-associated Diabetic Ketoacidosis: Clinical Review and Recommendations for Prevention and Diagnosis.钠-葡萄糖协同转运蛋白2抑制剂相关糖尿病酮症酸中毒：临床综述及预防与诊断建议
Clin Ther. 2016 Dec;38(12):2654-2664.e1. doi: 10.1016/j.clinthera.2016.11.002.
9
SGLT2 Inhibitors: A Systematic Review of Diabetic Ketoacidosis and Related Risk Factors in the Primary Literature.钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂：对原发性文献中糖尿病酮症酸中毒及相关危险因素的系统评价
Pharmacotherapy. 2017 Feb;37(2):187-194. doi: 10.1002/phar.1881. Epub 2017 Jan 16.
10
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS.美国临床内分泌医师协会和美国内分泌学会关于钠-葡萄糖协同转运蛋白2（SGLT-2）抑制剂与糖尿病酮症酸中毒相关性的立场声明
Endocr Pract. 2016 Jun;22(6):753-62. doi: 10.4158/EP161292.PS. Epub 2016 Jun 1.
Zotero 插件